DNA topoisomerase II structures and anthracycline activity: Insights into ternary complex formation

Current Pharmaceutical Design

Volumn 13, Issue 27, 2007, Pages 2766-2780

  Dal Ben, D ^a   Palumbo, M ^b   Zagotto, G ^b   Capranico, G ^c   Moro, Stefano ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anthracycline; DNA Topoisomerase; Molecular modelling; Topoisomerase poisons

Indexed keywords

ACLARUBICIN; AMSACRINE; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; DOUBLE STRANDED DNA; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; MERBARONE; MITOXANTRONE; NOVOBIOCIN; PIRARUBICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAZOXANE; SURAMIN; TENIPOSIDE; ANTHRACYCLINE;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CARDIOMYOPATHY; CARDIOTOXICITY; COMPLEX FORMATION; CONGESTIVE HEART FAILURE; CRYSTAL STRUCTURE; CYTOTOXICITY; DNA PROTEIN COMPLEX; DRUG DISTRIBUTION; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME STRUCTURE; GENE MUTATION; HUMAN; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTHRACYCLINES; BINDING SITES; DNA TOPOISOMERASES, TYPE II; HUMANS;

EID: 35748968504     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781757105     Document Type: Review

References (68)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65: 635-92.
2. Champoux JJ. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369-413.
3. Giaever GN, Snyder L, Wang JC. DNA supercoiling in vivo. Biophys Chem 1988; 29: 7-15.
4. Berger JM. Type II DNA topoisomerases. Curr Opin Struct Biol 1998; 8: 26-32.
5. Wang J. Cellular roles of DNA Topoisomerases: A molecular perspective. Mol Cell Biol 2002; 3: 430-41.
6. Porter AC, Farr CJ. Topoisomerase II: Untangling its contribution at the centromere. Chromosome Res 2004; 12: 569-83.
7. Brown PO, Peebles CL, Cozzarelli NR. A topoisomerase from Escherichia coli related to DNA gyrase. Proc Natl Acad Sci USA 1979; 76: 6110-4
8. Adams DE, Shekhtman EM, Zechiedrich EL, Schmid MB, Cozzarelli NR. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell 1992; 71: 277-88.
9. Gadelle D, Filee J, Buhler C, Forterre P. Phylogenomics of type II DNA topoisomerases. Bioessays 2003; 25: 232-42.
10. Bergerat A, de Massy B, Gadelle D, Varoutas PC, Nicolas A, Forterre P. An atypical topoisomerase IIfrom Archaea with implications for meiotic recombination. Nature 1997; 386: 414-7.
11. Nichols MD, DeAngelis K, Keck JL, Berger JM. Structure and function of an archaeal topoisomerase VI subunit with homology to the meiotic recombination factor Spo11. EMBO J 1999; 18: 6177-88.
12. Goto T, Wang JC. Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings. J Biol Chem 1982; 257: 5866-72.
13. Holm C, Goto T, Wang JC, Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell 1985; 41: 553-63.
14. Uemura T, Morikawa K, Yanagida M. The nucleolide sequence of the fission yeast DNA topoisomerase II gene: Structural and functional relationships to other DNA topoisomerases. EMBO J 1986; 5: 2355-61.
15. Tan KB, Dorman TE, Falls KM, Chung TD, Mirabelli CK, Crooke ST, et al. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 1992; 52: 231-4.
16. Null AP, Hudson J, Gorbsky GJ. Both alpha and beta isoforms of mammalian DNA topoisomerase II associate with chromosomes in mitosis. Cell Growth Differ 2002; 13: 325-33.
17. Larsen AK, Skladanowski A, Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res 1996; 2: 229-39.
18. Warburton PE, Earnshaw WC. Untangling the role of DNA topolsomerase II in mitotic chromosome structure and function. Bioessays 1997; 19: 97-9.
19. Solovyan VT, Bezveryuk ZA, Salminen A, Austin CA, Courtney, MJ. The role of to poisomerase II in the excision of DNA loop domains during apoptosis. J Biol Chem 2002; 277: 21459-67.
20. Andoh T, Sato M, Narita T, Ishida R. Role of DNA topoisomerase II in chromosome dynamics in mammalian cells. Biotechnol Appl Biochem 1993; 18 (Pt 2): 165-74.
21. Poljak L, Kas E. Resolving the role of topoisomerase II in chromatin structure and function. Trends Cell Biol 1995; 5: 348-54.
22. Larsen AK, Escargueil AE, Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res 2003; 5: 295-300.
23. Austin CA, Marsh KL. Eukaryotic DNA topoisomerase II beta. Bioessays 1998; 20: 215-26.
24. Tsutsui K, Tsutsui K, Sano K, Kikuchi A, Tokunaga A. Involvement of DNA topoisomerase IIb in neuronal differentiation. J Biol Chem 2001; 276: 5769-78.
25. Schvartzman JB, Stasiak A. A topological view of the replicon. EMBO Rep 2004; 5: 256-61.
26. Espeli O, Marians KJ. Untangling intracellular DNA topology. Mol Microbiol 2004; 52: 925-31.
27. Vologodskii AV, Zhang W, Rybenkov VV, Podtelezhnikov AA, Subramanian D, Griffith JD, et al. Mechanism of topology simplification by type II DNA topoisomerases. Proc Natl Acad Sci USA 2001; 98: 3045-9.
28. Rybenkov W, Ullsperger C, Vologodskii AV, Gozzarelli NR. Simplification of DNA topology below equilibrium values by type II topoisomerases. Science 1997; 277: 690-3.
29. Cortes F, Pastor N, Mateos S, Dominguez I. Roles.of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 2003; 543: 59-66.
30. Gatto B, Capranico G, Palumbo M. Drugs acting on DNA topoisomerases: recent advances and future perspectives. Curr Pharm Des 1999; 5: 195-215.
31. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99: 167-81.
32. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998; 1400: 155-71.
33. DNA topoisomerase II inhibitors. IARC Monogr Eval Carcinog Risks Hum 2000; 76: 175-344.
34. Hande KR. Topoisomerase II inhibitors. Cancer Chemother Biol Response Modif 2003; 21: 103-25.
35. Capranico G, Binaschi M, Borgnetto ME, Zunino F, Palumbo M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol Sci 1997; 18: 323-9.
36. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
37. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, et al. Anthracyclines: Selected new developments. Curr Med Chem Anticancer Agents 2001; 1: 113-30.
38. Mordente A, Meucci E, Maztorana GE, Giardina B, Minotti G. Human heart cytosolic reductascs and anthracycline cardiotoxicity. IUBMB Life 2001; 52: 83-8.
39. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents 2003; 3: 151-71.
40. Hargrave RM, Davey MW, Davey RA, Kidman AD. Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anticancer Drugs 1995; 6: 432-7.
41. Guano F, Pourquier P, Tinelli S, Binaschi M, Bigioni M, Animati F, et al. Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol 1999; 56: 77-84.
42. Moro S, Beretta GL, Dal Ben D, Nitiss J, Palumbo M, Capranico G. Interaction model for anthracycline activity againgt DNA topoisomerase II. Biochemistry 2004; 43: 7503-13.
43. Classen S, Olland S, Berger JM. Structure of the topoisomerase II. ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci USA 2003; 100: 10629-34.
44. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996; 379: 225-32.
45. Fass D, Bogden CE, Berger JM. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat Struct Biol 1999; 6: 322-6.
46. Brino L, Urzhumtsev A, Mousli M, Bronner C, Mitschler A, Oudet P, et al. Dimerization of Escherichia coli DNA-gyrase B provides a struciural mechanism for activating the ATPase catalytic center. J Biol Chem 2000; 275: 9468-75.
47. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC. Crystal structure of the breakage-reunion domaim of DNA gyrase. Nature 1997; 388: 903-6.
48. Corbett KD, Shultzaberger RK, Berger JM. The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold. Proc Natl Acad Sci USA 2004; 101: 7293-8.
49. Noble CG, Maxwell A. The role of GyrB in the DNA cleavage-religation reaction of DNA Gyrase: A proposed two metal-ion mechanism. J Mol Biol 2002; 318: 361-71.
50. Changela A, DiGate RJ, Mondragon A: Crystal structure of a complex of a type IA DNA topoisomerase with a single-stranded DNA molecule. Nature 2001; 411: 1077-81.
51. Schulz SC, Shields GC, Steitz TA. Crystal structure of a CAP-DNA complex: The DNA is bent by 90°. Science 1991; 253: 1001-07.
52. Berger JM, Fass D, Wang JC, Harrison SC. Structural similarities between topoisomerases that cleave one or both DNA strands. Proc Natl Acad Sci USA 1998; 95: 7876-81.
53. Sinha BK, Politi PM. Anthracyclines. Cancer Chemother Biol Response Modif 1990; 11: 45-57.
54. Capranico G, Supino R, Binaschi M, Capolongo L, Grandi M, Suarato A, et al. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol Pharmacol 1994; 45: 908-15.
55. Capranico G, Zunino F, Kohn KW, Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 1990; 29: 562-9.
56. Yakovleva L, Handy CJ, Sayer JM, Pirrung K Jerina DM, Shuman S. Benzo[c]phenanthrene Adducts and Nogalamycin Inhibit DNA Transesterification by Vaccinia Topoisomerase. J Biol Chem 2004; 279: 23335-42.
57. Khan QA, Kohlhagen G, Marshall R, Austin CA, Kalena GP, Kroth H, et al. Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: Implications for interactions with intercalating anticancer agents. Proc Natl Acad Sci USA 2003; 100: 12498-503.
58. Bromberg KD, Burgin AB, Osheroff N. A Two-drug Model for Etoposide Action against Human Topoisomerase IIa. J Biol Chem 2003; 278: 7406-12.
59. Leonard GA, Hambley TW, McAuley-Hecht K, Brown T, Hunter WN. Anthracycline-DNA interactions at unfavourable base base-pair triplet-binding sites: Structures of d(CGGCCG)/Daunomycin and d(TGGCCA)/ Adriamycin complexes. Acts Crystallogr D Biol Crystallogr 1993; 49: 458.
60. Capranico, G, Butelli E, Zunino F. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res 1995; 55: 312-7.
61. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluorequinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: Role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob, Agents Chemother 2001; 45: 2263-8.
62. Leontiou C, Lakey JH, Austin CA. Mutatipn E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4′-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4′-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide. Mol Pharmacol 2004; 66: 430-9.
63. Dong J, Walker J, Nitiss JL. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J Biol Chem 2000; 275: 7980-7.
64. Hsiung Y, Elsea SH, Osheroff N, Nitiss JL. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J Biol Chem 1995; 270: 20359-64.
65. Gruger T, Nitiss JL, Maxwell A, Zechiedrich EL, Heisig P, Seeber S, et al. A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II, Antimicrob Agents Chemother 2004; 48: 4495-504.
66. Ishikawa, T, Ikegami Y, Sano K, Nakagawa H, Sawada, S. Transport mechanism-based drug molecular design novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des 2006; 12(3): 313-25.
67. Moro S, Deflorian F, Bacilieri M, Spalluto G. Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity. Curr Pharm Des 2006; 12(17): 2175-85.
68. You Y. Podophyllotoxin derivatives: Current synthetic approaches for new anticancer agents. Curr Pharm Des 2005; 11(13): 1695-717.